Showing results (11-20 of 35) with videos related to
Sort By:
Pageof 4
Toxicologic Pathology|March 17, 2007
Administration of an antagonist of neurokinin receptors 1, 2, and 3 results in reproductive tract changes in beagle dogs, but not ratsPatricia E Losco, Michael W Leach, Dineshwar Sinha, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytesShu-Cheng Chen, Michael W Leach, Yuetian Chen, et al.Regulatory Toxicology and Pharmacology : RTP|March 26, 2018
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumabMarjorie A Peraza, Karen E Rule, Michael H I Shiue, et al.Toxicology and Applied Pharmacology|February 12, 2024
Translation of nonclinical to clinical safety findings for 27 biotherapeuticsMichael W Leach, Payal Rana, Wenyue Hu, et al.Regulatory Toxicology and Pharmacology : RTP|February 2, 2020
Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumabMazin Derzi, Ahmed M Shoieb, Sharon L Ripp, et al.Journal of Translational Medicine|April 28, 2010
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeysYulia Vugmeyster, Scott Allen, Pamela Szklut, et al.Toxicologic Pathology|February 28, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. BiotherapeuticsKendall S Frazier, Jeffery A Engelhardt, Pierluigi Fant, et al.Toxicologic Pathology|February 27, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense OligonucleotidesJeffery A Engelhardt, Pierluigi Fant, Silvia Guionaud, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 9, 2014
Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®))Susan Hurst, Anne M Ryan, Chee-Keng Ng, et al.Toxicologic Pathology|January 30, 2025
Scientific and Regulatory Policy Committee Points to Consider: Proposal and Recommendations to Reduce Euthanasia of Control Nonhuman Primates in Nonclinical Toxicity StudiesMagali Guffroy, Tara Arndt, Erio Barale-Thomas, et al.Pageof 4